Key Summary
- Oxford Pharmacy Store has been appointed as IBSA UK&I’s primary NHS distribution partner and will handle orders and supply to NHS customers, supported directly by IBSA UK&I.
- Ialuril will continue to be available via AAH Pharmaceuticals and Alliance as an alternative distribution channel.
- The transition follows IBSA establishing its UK affiliate in 2022, allowing direct management of commercial activities.
Swiss pharmaceutical company IBSA's UK subsidiary, IBSA UK&I, has announced that it will assume direct responsibility for the commercialisation and distribution of ialuril in the United Kingdom and Ireland from Thursday (9).
Over the past decade, Aspire Pharma had represented IBSA across the UK and Ireland, supporting the availability of ialuril to healthcare providers.
IBSA continues to manufacture ialuril, a pre-filled syringe to treat conditions caused by the loss of components in the bladder lining, and its latest move is expected to ensure continuity of supply.
Oxford Pharmacy Store (OPS) has been appointed as IBSA UK&I’s primary NHS distribution partner and will handle orders and supply to NHS customers, supported directly by IBSA UK&I.
Ialuril will continue to be available via AAH Pharmaceuticals and Alliance as an alternative distribution channel.
The transition follows IBSA's establishment of its UK affiliate in 2022, which allows direct management of commercial activities.
Bringing ialuril under direct management aligns it with IBSA’s expanding UK & Ireland uro-gynaecology portfolio, including Hyaluxelle and Perovial.
There is no change to the product formulation or its clinical use.
Ialuril continues to be used as a therapy to re-establish the glycosaminoglycan layers of the urothelial vesical tissue in cases where their loss can cause frequent and recurring problems like cystitis of varying etiology.
IBSA UK&I general manager Steven Knapp said, “We are pleased to take on direct responsibility for ialuril in the UK and Ireland. This transition reflects IBSA’s growing commitment to the urology and uro-gynaecology therapy area and allows us to work more closely with healthcare professionals and NHS partners.
"Our focus is on ensuring continuity of supply and strengthening the support we provide to clinicians so that patients can continue to access effective treatment.”
